CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
29.95
+0.59 (2.01%)
At close: Feb 4, 2025, 4:00 PM
31.02
+1.07 (3.57%)
After-hours: Feb 4, 2025, 4:47 PM EST
CG Oncology Revenue
CG Oncology had revenue of $43.00K in the quarter ending September 30, 2024, with 377.78% growth. This brings the company's revenue in the last twelve months to $684.00K. In the year 2023, CG Oncology had annual revenue of $204.00K with 6.81% growth.
Revenue (ttm)
$684.00K
Revenue Growth
+6.81%
P/S Ratio
n/a
Revenue / Employee
$11,213
Employees
61
Market Cap
2.28B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 204.00K | 13.00K | 6.81% |
Dec 31, 2022 | 191.00K | -10.17M | -98.16% |
Dec 31, 2021 | 10.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCGON News
- 7 weeks ago - CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 7 weeks ago - CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene - Seeking Alpha
- 7 weeks ago - CG Oncology Announces Pricing of Public Offering - GlobeNewsWire
- 2 months ago - CG Oncology Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer - Reuters
- 2 months ago - SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - GlobeNewsWire
- 2 months ago - Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 5 months ago - CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire